Clinomics Past Earnings Performance
Past criteria checks 0/6
Clinomics's earnings have been declining at an average annual rate of -35.4%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 7.9% per year.
Key information
-35.4%
Earnings growth rate
-19.8%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | -7.9% |
Return on equity | -98.8% |
Net Margin | -370.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Clinomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 11,408 | -42,257 | 30,716 | 1,941 |
30 Sep 23 | 14,597 | -25,309 | 19,268 | 2,213 |
30 Jun 23 | 14,334 | -23,018 | 19,741 | 2,366 |
31 Mar 23 | 14,786 | -15,626 | 14,359 | 2,740 |
31 Dec 22 | 23,083 | -10,177 | 13,918 | 3,142 |
30 Sep 22 | 46,127 | 6,013 | 13,072 | 3,399 |
30 Jun 22 | 60,886 | 14,102 | 12,469 | 3,289 |
31 Mar 22 | 64,265 | 17,706 | 11,158 | 2,959 |
31 Dec 21 | 55,426 | 15,853 | 10,184 | 2,852 |
30 Sep 21 | 29,106 | -409 | 9,543 | 3,300 |
30 Jun 21 | 12,785 | -8,175 | 8,527 | 3,432 |
31 Mar 21 | 12,848 | -11,108 | 9,320 | 3,748 |
31 Dec 20 | 9,820 | -13,147 | 9,229 | 4,045 |
30 Sep 20 | 9,152 | -11,525 | 7,936 | 3,102 |
31 Mar 20 | 4,327 | -7,725 | 5,368 | 1,859 |
Quality Earnings: A352770 is currently unprofitable.
Growing Profit Margin: A352770 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A352770 is unprofitable, and losses have increased over the past 5 years at a rate of 35.4% per year.
Accelerating Growth: Unable to compare A352770's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A352770 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A352770 has a negative Return on Equity (-98.81%), as it is currently unprofitable.